Global status of Middle East respiratory syndrome coronavirus in dromedary camels: a systematic review

R. S. Sikkema1-, E. A. B. A. Farag2-,*, Mazharul Islam3, Muzzamil Atta3, C. B. E. M. Reusken1, Mohd M. Al-Hajri2 and M. P. G. Koopmans1

1Department of Viroscience, Erasmus University Medical Center, Rotterdam, The Netherlands; 2Ministry of Public Health, Doha, Qatar and 3Department of Animal Resources, Ministry of Municipality and Environment, Doha, Qatar

Abstract
Dromedary camels have been shown to be the main reservoir for human Middle East respiratory syndrome (MERS) infections. This systematic review aims to compile and analyse all published data on MERS-coronavirus (CoV) in the global camel population to provide an overview of current knowledge on the distribution, spread and risk factors of infections in dromedary camels. We included original research articles containing laboratory evidence of MERS-CoV infections in dromedary camels in the field from 2013 to April 2018. In general, camels only show minor clinical signs of disease after being infected with MERS-CoV. Sero-epidemiological evidence of MERS-CoV in camels has been found in 20 countries, with molecular evidence for virus circulation in 13 countries. The seroprevalence of MERS-CoV antibodies increases with age in camels, while the prevalence of viral shedding as determined by MERS-CoV RNA detection in nasal swabs decreases. In several studies, camels that were sampled at animal markets or quarantine facilities were seropositive more often than camels at farms as well as imported camels vs. locally bred camels. Some studies show a relatively higher seroprevalence and viral detection during the cooler winter months. Knowledge of the animal reservoir of MERS-CoV is essential to develop intervention and control measures to prevent human infections.

Introduction
Middle East respiratory syndrome (MERS) is a highly fatal respiratory tract disease in humans that was first detected in 2012 in the Kingdom of Saudi Arabia (KSA) [1]. After its first detection, MERS-coronavirus (MERS-CoV) was being reported in human patients across the Arabian Peninsula, with occasional travel-related cases in other continents. As of the end of March 2018, a total of 2189 human laboratory-confirmed cases from 27 countries have been reported to the World Health Organisation (WHO), including 782 associated deaths [2]. Dromedary camels (Camelus dromedaries) have been shown to be the natural reservoir from where spill-over to humans can occur [3, 4]. Human-to-human infection is also reported frequently, especially in healthcare settings [5]. Sustained human-to-human transmission outside of hospital settings has not been shown yet [6]. Direct or indirect human contact with camels has resulted in repeated introductions of MERS-CoV into the human population [7]. It has been suggested that camels may have acquired MERS-CoV from a spill-over event from a bat reservoir, but evidence for that remains inconclusive [8]. Infections with MERS-CoV generally are thought to be mild or inapparent in camels [9], and are therefore of low economical or animal welfare significance.

This systematic review was done to compile and analyse all published data on MERS-CoV in the global camel population to provide an overview of current knowledge on the distribution, spread and risk factors of MERS-CoV infections in dromedary camels as a basis for the design of intervention and control measures to prevent human infections.

Material and methods
On 2 May 2018, a literature search on PubMed was performed, using the terms 'middle east respiratory syndrome coronavirus' and 'MERS-CoV'. Using the term 'MERS' did not result in any additional articles that fit the scope of this review. Only articles published in English were included. Two reviewers individually selected all original research articles containing laboratory evidence of MERS-CoV infections in dromedary camels in the field. Articles that were mentioned in Food and Agriculture Organization (FAO) updates [10] or in the references of included publications, but did not appear in the PubMed search were added.
Subsequently, abstracts, follow-up studies of MERS-CoV-positive camels and genome studies without prevalence data were excluded from the analysis. Data on variables such as year of sampling, country, region, age, sex and animal origin were extracted and analysed. For each variable, the number of positive camels, total number of camels tested and the median percentage positivity was calculated. Data from experimental infection studies were not included in this analysis, but they were included in the review to provide additional information and context to the field studies. Additional information on the distribution and trade of dromedary camels was collected from references in the publications on MERS-CoV in camels and extracted from official FAO and World Organisation for Animal Health (OIE) databases [11, 12]. The additional literature on camel trade was collected in a less systematic way from PubMed.

**Results**

**Literature search**

The literature search resulted in a total of 53 papers (Fig. 1). Forty-three research papers described the results of cross-sectional studies in dromedary camel populations, six papers described outbreak investigations, including an analysis of camel samples, and four papers described longitudinal studies. In total, 33 papers describe camel studies in the Middle East, 13 studies investigated camels from Africa and the remaining seven surveys were from Spain, Australia, Japan, Bangladesh and Pakistan (Table 1).

**Distribution and trade of camels**

Most recent FAO statistics estimate the world population of camel to be around 29 million [11], of which approximately 95% are dromedary camels [13]. However, it is believed that the true population size is even larger due to inaccurate statistics and feral camels, such as the feral dromedary camel population in Australia that is estimated to be around 1 million [14]. Over 80% of the camel population lives in Africa. The main camel countries are Chad (6,400,000), Ethiopia (1,200,000), Kenya (2,986,057), Mali (1,028,700), Mauritania (1,379,417), Niger (1,698,110), Sudan (4,830,000), Somalia (7,100,000) and Pakistan (1,000,000) [12] (Table 2).

A large number of camels are being transported from the Horn of Africa to the Middle East each year. These are mainly meat camels coming from the east of Africa going to Egypt, Libya and the Gulf states, and Sudanese camels that are being imported into the Middle East to participate in camel racing competitions [15]. For example, the FAO reported that Somalia exported 77,000 camels in 2014 [16]. The largest camel market in Africa is the Birqash market near Cairo (Egypt), where camels from Sudan and Ethiopia are most common, but trade routes include animals from Chad, Somalia, Eritrea and Kenya [17]. Imported camels are usually quarantined for 2–3 days at the border before they are allowed to enter Egypt [17]. Most Somali and Sudanese camels that are exported to the KSA are shipped from the ports of Berbera and Bosaso in North Somalia to the KSA ports of Jizan and Jeddah [15].

**Clinical and pathological features of MERS-CoV infections in dromedary camels**

In general, only minor clinical signs of disease have been observed in animals infected with MERS-CoV and most MERS-CoV infections do not appear to cause any symptoms [9]. Disease symptoms that have been described after experimental and field infections are coughing and sneezing, respiratory discharge, fever and loss of appetite [18–20]. Although MERS-CoV RNA can be detected in several organs after experimental infection, in studies of natural infectious virus it has only been detected in the tissues of the upper and lower respiratory tract and regional lymph nodes of the respiratory system in part of the infected camels. Histologically, a mild-to-moderate inflammation and necrosis could also be seen on the upper and lower respiratory tract. No viral antigen or lesions were detected in the alveoli. Histopathological examination showed that the nasal respiratory epithelium is the principal site of MERS-CoV replication in camels [18, 21].

**Virus shedding and antibody response**

In one study investigating experimental infection of camels, MERS-CoV shedding started 1–2 days post-infection (dpi). In that study, infectious virus could be detected until 7 dpi, and viral RNA until 35 dpi in nasal swab samples and, in lower
| References            | Study design          | Country of origin | Year            | MERS-CoV RNA presence | MERS-CoV seroprevalence | Sex | Age | Imported/local | Sampling location | Other animals tested |
|-----------------------|-----------------------|-------------------|-----------------|-----------------------|--------------------------|-----|-----|----------------|-------------------|---------------------|
| Hemida et al. [50]    | Cross-sectional      | KSA               | 2010-2013       | ppNT: 90% (280/310)   | <1Y: 72% [47/65]          |     |     |                |                   | Sheep 0% (0/100)   |
|                       |                       |                   |                 |                       | 1–3Y: 95% [101/106]       |     |     |                |                   | Goat 0% (0/45)     |
|                       |                       |                   |                 |                       | 4–5Y: 97% [74/76]         |     |     |                |                   | Chicken 0% (0/240) |
|                       |                       |                   |                 |                       | >5Y: 92% [58/63]          |     |     |                |                   | Cattle 0% (0/56)   |
| Perera et al. [48]    | Cross-sectional      | Egypt             | 2013            | MN: 98% (108/110)     |                          |     |     |                | Abattoir           | Goat 0% (0/123)    |
|                       |                       |                   |                 |                       | Sheep 0% (0/5)            |     |     |                |                   | Buffalo 0% (0/8)   |
|                       |                       |                   |                 |                       | Cattle 0% (0/25)          |     |     |                |                   | Swine 0% (0/260)   |
|                       |                       |                   |                 |                       | Wild birds (Hong Kong) 0%|     |     |                |                   | (0/204)            |
| Reusken et al. [4]    | Cross-sectional      | Oman              | 2013            | pMA: 100% (50/50)     | Female: 100% (50/50)     |     |     | Local          | Breeding farm      | Bactrian camel 0% (0/4) |
|                       |                       | Spain (Canary      | 2012–2013       |                       | Male: 4% (2/50)           |     |     |                |                  | Alpaca 0% (0/24)   |
|                       |                       | islands)          |                 |                       | Female: 13% (7/55)        |     |     |                |                  | Llama 0% (0/7)     |
|                       |                       |                   |                 |                       | 14% (15/105)              |     |     |                |                  | Guanaco 0% (0/2)   |
|                       |                       |                   |                 |                       |                           |     |     |                |                  | Cattle 0% (0/40)   |
|                       |                       |                   |                 |                       |                           |     |     |                |                  | Sheep 0% (0/40)    |
| Reusken et al. [51]   | Cross-sectional      | Jordan            | 2013            | Faecal: 0% (0/11)     | pMA: 100% (11/11)         |     |     | 3–14m: 109% (11/11) | Sheep 0% (0/126) | PCR: 5% (6/126); 0% |
|                       |                       |                   |                 |                       | Male: 100% (11/11)        |     |     |                |                  | (0/126) Cattle: 0% |
|                       |                       |                   |                 |                       |                           |     |     |                |                  | PCR: 0% (0/91)    |
|                       |                       |                   |                 |                       |                           |     |     |                |                  | Goat: pMA: 0% (0/150) |
| Alagaili et al. [31]  | Cross-sectional      | KSA               | 1992            | ELISA: 100% (1/1)     |                         |     |     |                |                   | Goat: PCR 0% (0/36) |
|                       |                       |                   | 1993            | 100% (2/2)            |                           |     |     |                |                   | ELISA 0% (0/35)    |
|                       |                       |                   | 1994            | 93% (114/123)         |                           |     |     |                |                   | ELISA 0% (0/35)    |
|                       |                       |                   | 1996            | 100% (6/6)            |                           |     |     |                |                   | ELISA 0% (0/35)    |
|                       |                       |                   | 2004            | 100% (6/6)            |                           |     |     |                |                   | ELISA 0% (0/35)    |
|                       |                       |                   | 2009            | 78% (64/82)           |                           |     |     |                |                   | ELISA 0% (0/35)    |
|                       |                       |                   | 2010            | 84% (37/44)           |                           |     |     |                |                   | ELISA 0% (0/35)    |
|                       |                       |                   | 2013            | 74% (156/203)         |                           |     |     |                |                   | ELISA 0% (0/35)    |
|                       |                       |                   |                 | ELISA: 100% (1/1)     |                         |     |     |                |                   | ELISA 0% (0/35)    |
|                       |                       |                   |                 | 100% (2/2)            |                           |     |     |                |                   | ELISA 0% (0/35)    |
|                       |                       |                   |                 | 93% (114/123)         |                           |     |     |                |                   | ELISA 0% (0/35)    |
|                       |                       |                   |                 | 100% (6/6)            |                           |     |     |                |                   | ELISA 0% (0/35)    |
|                       |                       |                   |                 | 100% (6/6)            |                           |     |     |                |                   | ELISA 0% (0/35)    |
|                       |                       |                   |                 | 78% (64/82)           |                           |     |     |                |                   | ELISA 0% (0/35)    |
|                       |                       |                   |                 | 84% (37/44)           |                           |     |     |                |                   | ELISA 0% (0/35)    |
|                       |                       |                   |                 | 74% (156/203)         |                           |     |     |                |                   | ELISA 0% (0/35)    |
|                       |                       |                   |                 | <2Y: 52% [50/96]      |                         |     |     |                |                   |                  |
|                       |                       |                   |                 | 2–5Y: 88% (20/23)     |                         |     |     |                |                   |                  |
|                       |                       |                   |                 | >5Y: 98% [54/55]       |                         |     |     |                |                   |                  |
| Alexandersen et al. [49] | Cross-sectional   | UAE               | 2005            | VNT/ELISA: 82% (9/11) | Male: 50% (2/4)           |     |     |                | Sheep 0% (0/20)   | Horse 0% (0/3)    |
|                       |                       | USA and Canada    | 2000–2001       | 0% (0/6)              | Female: 100% (7/7)        |     |     |                |                   |                  |
| Azhar et al. [66]     | Human outbreak      | KSA               | 2013            | Nasal: 11% (1/9)      | IFA/ELISA: 100% (9/9)     |     |     |                | Farm              |                  |
|                       | investigation       |                   |                 | Milk, urine, rectal: 0%|                           |     |     |                |                   |                  |
|                       |                       |                   |                 | (0/11)                |                           |     |     |                |                   |                  |
|                       |                       |                   |                 | IFA/ELISA: 100% (1/1) |                           |     |     |                |                   |                  |
|                       |                       |                   |                 | 100% (2/2)            |                           |     |     |                |                   |                  |
|                       |                       |                   |                 | 100% (2/2)            |                           |     |     |                |                   |                  |
| Chu et al. [9]        | Multiple cross-      | Egypt             | 2014            | ppNT: 92% (48/52)     |                          |     |     |                | Abattoir          |                  |
|                       | sectional            |                   |                 | >6Y: 92% (48/52)       |                          |     |     |                |                   |                  |
|                       |                       |                   |                 | Nasal: 0% (0/17)      |                          |     |     |                |                   |                  |

(Continued)
| References                | Study design | Country of origin | Year       | MERS-CoV RNA presence | MERS-CoV seno-prevalence | Sex | Age | Imported/local | Sampling location | Other animals tested |
|--------------------------|--------------|-------------------|------------|-----------------------|--------------------------|-----|-----|----------------|---------------------|---------------------|
| Corman et al. [36]       | Cross-sectional | Kenya             | Total      | ELISA, total: 30% (226/744) | Adult: 37% (226/700)     |     |     |                |                     |                     |
|                          |              |                   | 1992       | 5% (1/22)             |                          |     |     |                |                     |                     |
|                          |              |                   | 1996       | 5% (2/37)             |                          |     |     |                |                     |                     |
|                          |              |                   | 1998       | 3% (2/62)             |                          |     |     |                |                     |                     |
|                          |              |                   | 1999       | 27% (71/266)          |                          |     |     |                |                     |                     |
|                          |              |                   | 2000       | 32% (82/258)          |                          |     |     |                |                     |                     |
|                          |              |                   | 2007       | 0% (0/28)             |                          |     |     |                |                     |                     |
|                          |              |                   | 2008       | 56% (103/183)         |                          |     |     |                |                     |                     |
|                          |              |                   | 2013       | 17% (8/47)            |                          |     |     |                |                     |                     |
| Haagmans et al. [3]      | Human outbreak investigation | Qatar         | 2013       | Nasal: 86% (12/14) Oral: 0% (0/14) Rectal: 0% (0/19) | IFA/VNT: 100% (14/14) |     |     | Farm          |                     |                     |
| Hemida et al. [19]       | Longitudinal | KSA               | 2013–2014  | Nasal: 33% (9/27) Oral: 0% (0/17) Rectal: 3% (1/37) | <2Y: 39% (7/18) 6–14Y: 22% (2/9) |     |     | Farm          |                     |                     |
| Hemida et al. [68]       | Cross-sectional | KSA             | 1993       | ppNT: 90% (118/131) |                          |     |     |                |                     |                     |
|                          |              |                   | 2014       | ppNT: 0% (0/25)       |                          |     |     |                |                     |                     |
|                          |              |                   | Egypt      | ppNT: 100% (7/7)      |                          |     |     |                |                     |                     |
| Meyer et al. [37]        | Cross-sectional | UAE             | 2003       | IFA: 100% (151/151) |                          | >2Y: 100% (151/151) |     |     | Bactrian camel 0% (0/16) |                     |                     |
|                          |              |                   | 2013       | IFA: 96% (483/500)   |                          | 2–8Y: 89% (89/100) |     |     | Farm (racing): 89% (89/100) |                     |                     |
|                          |              |                   |            |                       |                          | >2Y: 89% (89/100) |     |     | Farm (livestock camels): 100% (217/218) |                     |                     |
|                          |              |                   |            |                       |                          | Isolated: 8% (8/95) |     |     | KSA, Sudan, Pakistan, and Oman UAS |                     |                     |
| Muller et al. [32]       | Cross-sectional | Somalia          | 1983–1984  | ELISA: 84% (72/86) mNT: 81% (70/86) ELISA: 84% (159/189) mNT: 81% (153/189) ELISA: 81% (35/43) mNT: 79% (34/43) | Female: ELISA 84% (159/189) |     |     | Abattoir       |                     |                     |
|                          |              |                   | Sudan      | 1983       |                            |                        |     |     |                |                     |                     |
|                          |              |                   | Egypt      | 1997       |                            |                        |     |     |                |                     |                     |
| Novotny et al. [69]      | Cross-sectional | Oman             | 2013       | Nasal: 7% (5/76)       |                          |     |     |                |                     |                     |
| Raj et al. [70]          | Cross-sectional | Qatar            | 2014       | Nasal: 2% (1/53)       |                          |     |     |                |                     |                     |
| Reusken et al. [28]      | Cross-sectional | Qatar            | 2013       | Nasal: 15% (5/33) Rectal: 9% (3/33) Milk: 15% (3/33) | pMA: 100% (33/33) | Female: 15% (5/33) | >2Y: PCR 42% (5/12) ELISA 100% (12/12) | Farm |                     |
| Authors            | Type            | Country/Region | Year(s) | Age Groups | Diagnosis Methods | Positive Rates | Additional Notes |
|--------------------|-----------------|----------------|---------|------------|-------------------|----------------|------------------|
| Reusken et al. [28]  | Cross-sectional | Nigeria        | 2010-2011 | pMA: 28%   | pMA: 49% (99/204) | pMA: 96% (181/188) | 2010–2011        | Abattoir also serves Chad, Niger, CAR |
| Woo et al. [29]    | Cross-sectional | UAE            | 2013     | Faecal: 5% | WB: 98% (56/59)    | IFA: 100% (58/59) | <2Y: 30% (14/46)  | Farm |
| Al Hammadi et al. [71] | Human outbreak investigation | UAE       | 2015     | Nasal: 100% (8/8) | ppNT: 100% (5/5) | Female: 100% (5/5) | <1Y: 100% (4/4)  | Oman Border screening |
| Crameri et al. [58] | Cross-sectional | Australia      | 2013–2014 | VNT: 0%     | pMA: 50% (166/335) | <6m: 36% (22/61) | Abattoir: 231     | Farm: 48% (124/261) Nomadic: 57% (42/74) |
| Deem et al. [40]   | Cross-sectional | Kenya          | 2013     | pMA: 50%   | pMA: 97% (100/103) | <1Y: PCR: 68% (50/73) | Farm: 42% (15/36) | Abattoir |
| Gutierrez et al. [33] | Cross-sectional | Canary Islands | 2015     | ELISA: 4%   | Male: 0% (0/101) Female: 10% (7/69) | >2Y: 4% (7/170) | All positives were aged 20–26Y |
| Khalafalla et al. [20] | Longitudinal    | KSA            | 2013–2014 | Nasal: 29% Lung tissue 62% | ELISA: 0% (0/5) | Male: nasel PCR 0% (0/1) Female: nasal PCR 0% | <4Y: 42% (15/36) | Abattoir, live animal market, veterinary hospital |
| Shirato et al. [47] | Cross-sectional | Japan          | 2015     | Nasal: 0% Rectal: 0% Oral: 0% | ELISA: 0% (0/5) | Male: nasel PCR 0% (0/1) Female: nasel PCR 0% | <2Y: 0% (0/1) | Zoo Bactrian camels: PCR: 0% (0/6) ELISA: 0% (0/6) |
| Wernery et al. [55] | Cross-sectional | UAE            | 2015     | Nasal: 0% Milk: 0% | ELISA: 92% (234/254) Female: ELISA 99% (132/133) | 0–3m: ELISA: 75% (24/32) 4m: ELISA: 79% (11/14) 5–6m: ELISA: 89% (41/46) 7–12m: ELISA: 89% (26/29) >12m: ELISA: 89% (132/133) | Farm |
| References       | Study design | Country of origin | Year     | MERS-CoV RNA presence | MERS-CoV seroprevalence | Sex | Age       | Imported/local | Sampling location | Other animals tested |
|------------------|--------------|-------------------|----------|------------------------|-------------------------|-----|-----------|---------------|-------------------|---------------------|
| Wernery et al.   | Cross-sectional | UAE              | 2015     | Nasal: 5% (45/871)     | ELISA: 93% (786/843)    |     | <1Y: PCR: 35% (24/68) ELISA 85% (92/108) 2-4Y: PCR: 3% (10/344) ELISA 97% (328/340) >4Y: PCR: 0% (0/250) ELISA 96% (298/310) |     | Farm |
| Yusof et al.     | Cross-sectional | UAE              | 2014     | Nasal: 2% (126/7803)   | ELISA 85% (92/108)     |     | 2-4Y: PCR: 3% (10/344) ELISA 97% (328/340) >4Y: PCR: 0% (0/250) ELISA 96% (298/310) |     | Farm |
| Meyer et al.     | Longitudinal  | UAE               | 2014-2015 | At 6m (nasal): 18% (2/11) of calves, no dams | At day 0: MN/ELISA 0% (0/11) Maternal Ab peak at day 7 At 5-6m: 45% (5/11) At 12m: 100% (22/22) |     | Dams: ELISA: 100% (11/11) |
| Miguel et al.    | Cross-sectional | Kazakhstan      | 2015     | ppNT: 0% (0/455)       | Female: 0% (0/455)     |     |           | Farm |
| Muhairi et al.   | Human outbreak investigation | UAE       | 2014     | Farms MERS patients (n=2): Nasal: 10% (15/155) Surrounding farms: Nasal: 3% (2/71) |               |     |           | Farm |
| Sabir et al.     | Cross-sectional | KSA              | 2014-2015 | Nasal: 12% (159/1309) Rect: 0% (0/304) | ≤6m:15% (28/190) 6m-1Y: 18% (58/315) 1-2Y: 8% (42/509) 2-4Y: 10% (20/206) >4Y: 11% (5/46) |     | Local: 15% (133/893) Sudan: 6% (7/116) Somalia: 7% (19/291) Abattoir: 0% (0/14) Farm: 11% (14/133) Market: 12% (145/1162) |
| Al Salhi et al.  | Cross-sectional | Iraq             | 2015-2016 | 15% (15/100) (94 nasal, 6 oropharyngeal swabs) | Male: 18% (3/17) Female: 14% (12/83) |     | <1Y: 0% (0/9) 1-5Y: 15% (6/41) 5-10Y: 16% (6/38) >10Y: 25% (3/12) | Farm |
| Ali et al.       | Cross-sectional | Egypt            | 2014-2015 | Nasal: 15% (435/2825) Rect: 15% (28/184) Milk: 6% (12/187) Urine: 0% (0/26) | MN: 71% (1808/2541) Milk: 20% (38/187) Female: PCR 11% (115/1089) MN 66% (724/1090) |     | Local: PCR 12% (192/1658) MN 61% (1015/1650) Market: PCR 2.5% (4/159) MN 92% (159/172) Nomadic: PCR 1% (3/282) MN 72% (202/282) | Farm |


| Author(s) | Study Type | Country | Year | Location | Nasal | Rectal | Genital | ELISA | Seropositivity Rate | CR-positive Rate | Age Range | Gender | PCR Test | CR Test | Other Data |
|----------|------------|---------|------|----------|-------|--------|----------|-------|-------------------|----------------|------------|--------|----------|----------|------------|
| Ali et al. [27] | Cross-sectional | Egypt | 2014-2015 | Nasal: 4% (41/1078) | MN: 84% (871/1031) | Male: PCR 3% (21/798) | MN 85% (851/966) | Female: PCR 7% (20/280) | MN 83% (220/266) | ≤2Y: PCR 2% (2/82) MN 52% (42/82) | >2Y: PCR 4% (99/996) MN 87% (829/950) | Local: PCR 1% (2/340) MN 94% (273/289) | Village: PCR 2% (2/340) MN 76% (257/339) | East Africa: PCR 3% (4/115) MN 72% (77/98) | Sudan: PCR 0% (35/623) MN 91% (543/594) |
| | | | | | | | | | | | | | | | |
| Doremalen et al. [23] | Cross-sectional | Jordan | 2016 | Nasal: 7% (28/42) | Rectal: 0% (0/42) | Genital: 0% (0/42) | ELISA 82% (37/45) | <1Y: PCR 61% (11/18) | ELISA 79% (14/18) | 1–2Y: PCR 92% (22/24) | ELISA 69% (9/13) | 2–5Y: PCR 50% (5/10) | ELISA 100% (10/10) | >5Y: PCR 2% (4/164) | ELISA 100% (4/4) |
| | | | | | | | | | | | | | | | |
| Falzarano et al. [53] | Cross-sectional | Mali | 2009–2010 | Nasal: 8% (502/571) | Rectal: 0% (0/70) | Genital: 0% (0/70) | Male: 86% (210/245) | Female: 92% (302/328) | 1–2Y: 83% | 3–8Y: 91% | 9–16Y: 88% |
| | | | | | | | | | | | | | | | |
| Hemida et al. [24] | Longitudinal | KSA | 2014–2015 | Nasal: 4% (3/70) | Rectal: 0% (0/70) | ppNT: 100% (70/70) | Female: 92% (302/328) | 1–2Y: 83% | 3–8Y: 91% | 9–16Y: 88% |
| | | | | | | | | | | | | | | | |
| Kasem et al. [38] | Human outbreak investigation | KSA | 2014–2016 | Nasal: 10% (75/780) | Rectal: 0% (0/70) | ppNT: 100% (70/70) | Male: PCR 20% (49/245) | ELISA 64% (127/192) | Female: PCR 5% (26/515) | ELISA 67% (355/533) | ≤2Y: PCR 15% (46/298) | ELISA 57% (145/251) | 2–4Y: PCR 6% (13/202) | ELISA 79% (120/156) |
| | | | | | | | | | | | | | | | |
| Miguel et al. [39] | Cross-sectional | Burkina Faso Ethiopia Morocco | 2015 | Nasal: 5% (27/525) | Rectal: 0% (0/70) | Male: PCR 20% (14/25) | ELISA 64% (127/192) | Female: PCR 5% (26/515) | ELISA 67% (355/533) | ≤2Y: PCR 25% (46/298) | ELISA 57% (145/251) | 2–4Y: PCR 6% (13/202) | ELISA 79% (120/156) | 4–6Y: PCR 4% (6/144) | ELISA 81% (79/98) |
| | | | | | | | | | | | | | | | |
| Munyua et al. [75] | Cross-sectional | Kenya | 2013 | Nasal: 10% (70/632) | Rectal: 0% (0/70) | ppNT: 100% (632/632) | Male: 81% (173/213) | Female: 93% (616/664) | 1–4Y: 73% (209/285) | 4–6Y: 99% (116/117) | >6Y: 98% (466/476) |
| | | | | | | | | | | | | | | | |
| Saqib et al. [35] | Cross-sectional | Pakistan | 2012–2015 | Nasal: 10% (56/565) | Male: 44% (252/571) | ELISA 90% (502/557) | Female: 39% (223/565) | ≤2Y: MN 29% (26/89) | 2–5Y: 30% (62/208) | 5–10Y: 52% (91/178) | >10Y: 49% (43/88) |
| | | | | | | | | | | | | | | | |
| Yusuf et al. [41] | Cross-sectional | UAE | 2015 | Nasal: 10% (56/565) | Male: 44% (252/571) | ELISA 90% (502/557) | Female: 39% (223/565) | ≤2Y: MN 29% (26/89) | 2–5Y: 30% (62/208) | 5–10Y: 52% (91/178) | >10Y: 49% (43/88) |
| | | | | | | | | | | | | | | | |
Table 1. Continued.

| Study design       | Year   | Country of origin | MERS-CoV seroprevalence | MERS-CoV RNA presence | Reference |
|--------------------|--------|-------------------|--------------------------|-----------------------|-----------|
| Cross-sectional    | 2013-2017 | Israel             | Nasal: 0% (0/54) VNT: 62% (254/411) Male: 83% (77/93) Female: 87% (68/78) <2Y: ELISA/ppNT 9% (1/11) | ELISA: 31% (254/818) | Chu et al. [43] |
| Cross-sectional    | 2015-2017 | Israel             | Nasal: 5% (5/102)       | ELISA: 34% (35/102) VNT: 32% (30/94) | Kasem et al. [78] |
| Cross-sectional    | 2015-2017 | Ethiopia           | Nasal: 0% (0/19) VNT: 62% (254/411) Male: 83% (77/93) Female: 87% (68/78) <2Y: ELISA/ppNT 9% (1/11) | ELISA: 31% (254/818) | Chu et al. [43] |

MERS-CoV infections have also been detected in camels with MERS-CoV antibodies, both in calves with maternal antibodies as well as older camels that had already acquired antibodies from a previous infection. However, virus replication and thus the virus load is generally lower in infected seropositive animals compared with seronegative camels [19, 21, 23, 24, 30, 31].

Little is known about the longevity of antibody titres after infection from longitudinal studies. A study following camels on a closed farm found that neutralizing antibodies remained consistent during a year [30], while other studies found that antibody titres rapidly drop by 1–4-fold within a period often as short as 2 weeks [24, 27].

Worldwide distribution of MERS-CoV in dromedary camels

The first evidence of MERS-CoV in camels described so far is the detection of antibodies to MERS-CoV in camel sera from Somalia and Sudan from 1983 of which 81% tested positive [32]. Additional serological evidence of the widespread presence of MERS-CoV infection in camels, included in this review, has been found in 18 additional countries: Bangladesh, Burkina Faso, Egypt, Ethiopia, Iraq, Israel, Jordan, Kenya, KSA, Mali, Morocco, Nigeria, Oman, Pakistan, Qatar, Spain, Tunisia and the UAE (Fig. 2). In addition, Promed mail reported that virus-positive camels had been found in Kuwait and Iran, the latter reportedly in imported animals (Archive number 20140612.2534919 and 20141029.2912385). In 11 countries, serological findings were complemented with the finding of viral RNA in dromedary camels: Burkina Faso, Egypt, Ethiopia, Iraq, Israel, Jordan, KSA, Morocco, Nigeria, Oman, Qatar and the UAE. Investigations of MERS-CoV circulation amongst dromedary camels in Australia, Japan, Kazakhstan, USA and Canada did not find any proof of MERS-CoV circulation. All countries where MERS-CoV circulates in the camel population, with the exception of Spain (Canary Islands), Pakistan and Bangladesh, are located in the Middle East or Africa [4, 33]. One out of 17 camels that had MERS-CoV antibodies in Bangladesh was born in Bangladesh, 16 others were imported from India [34]. However, there have not been any additional reports of MERS-CoV in camels in India. There is no record of foreign origin of the seropositive camels from Pakistan [35]. Moreover, in previous studies there had already been evidence of seropositive camels that originate from Pakistan [37, 58].

https://doi.org/10.1017/S095026881800345X Published online by Cambridge University Press
When combining serology data from all papers included in this review, the overall median seroprevalence of camels in Africa is 81% (6106/8526; range 28–98%), compared with a median seroprevalence of 93% (3230/3846; range 53–100%) in camels from the Middle East. Based on viral shedding studies from African countries, the median rate of viral shedding was 5% (1108/6318; range 1–15%), compared with 12% in camels from the Middle East (1191/14902; range 0–100%).

### Risk factors of MERS-CoV in dromedary camels

#### Age

The seroprevalence of MERS-CoV antibodies increases with age in camels, while the fraction of camels that test positive for MERS-CoV RNA in their nasal swabs decreases with age [17, 31, 36, 38, 39]. When all serological results of papers that included sufficient age information is combined, the median seroprevalence of camels aged under 2 years is 52% (992/1972; range 0–100%), while the age groups 2–5 years (702/924; range 30–100%) and over 5 years old (1226/1370; range 0–100%) had a combined median seroprevalence of 97%. In the virological studies reporting age breakdown, the median rate of nasal shedding in 0–2 years old camels was 34% (718/2612; range 0–100%) of cases, compared with 2% (91/1142; range 0–100%) in camels older than 2 years.

#### Sex

Some individual studies show a significantly higher seroprevalence in female camels compared with males [27, 39], while others show the opposite [38] or do not find any significant difference [17, 35]. Similar disagreeing results are published for the presence of MERS-CoV RNA in male vs. female camels [17, 27, 38, 39].

In the studies in this review where sex of camels was recorded, a total of 4810 serum samples from female camels and 3458 samples from male camels were collected and analysed for MERS-CoV antibodies, compared with 2007 vs. 2505 nasal swabs for viral RNA testing. Approximately three times more female camels were sampled at farms, while male camels were in the majority in studies that looked at MERS-CoV prevalence of camels at slaughterhouses, live animal markets and quarantine areas. The overall median seroprevalence of male and female camels in our review is 50% and 67%, respectively (range 0–100%; excluding results from Israel and Kazakhstan). The median percentage of presence of viral RNA is 18% in nasal swabs of male camels (range 0–21%) compared with 9% in female camels (range 0–100%), in our review.

#### Sampling location and herd characteristics

In several studies, camels that were sampled at animal markets or quarantine facilities were seropositive more often than camels at farms [17, 22, 27, 34]. Combining serological laboratory results of camels in our review with sufficient background information with regard to the sampling location does not result in the same pattern, with a median seroprevalence of 84% (5632/8115; range 0–100%; excluding Australia and Spain) in camels from farms and 80% (943/1105; range 28–98%) in the camel population sampled at markets and quarantine facilities. Studies in Egypt found a significantly higher PCR positivity rate in camels sampled in abattoirs or quarantine facilities, but these results could not be confirmed by other papers in this review [17, 27].

When comparing differences in seroprevalence or virus RNA-positive rate in nomadic vs. sedentary camel herds, some authors did not find a statistical difference between the two herd management types [39, 40], while others found some evidence of higher seroprevalences in nomadic herds [27, 36]. One study in Kenya looked at the differences between herds with different levels of

### Table 2. Camel population and density

| Country                  | Camel population (OIE, 2016) | Camel density (OIE, 2016) (animals per square kilometre) |
|--------------------------|------------------------------|----------------------------------------------------------|
| **Africa**               |                              |                                                          |
| Algeria                  | 354 565 (OIE, 2014)          | 0.15 (OIE, 2014)                                         |
| Burkino Faso             | 19 097                       | 0.07                                                     |
| Djibouti                 | 50 000                       | 2.17                                                     |
| Egypt                    | 66 233                       | 0.07                                                     |
| Eritrea                  | 385 283                      | 3.18                                                     |
| Ethiopia                 | 1 200 000                    | 1.06                                                     |
| Kenya                    | 2 986 057                    | 5.12                                                     |
| Libya                    | 110 000                      | 0.06                                                     |
| Mali                     | 1 028 700                    | 0.83                                                     |
| Mauritania               | 1 379 417 (OIE, 2013)        | 1.34 (OIE, 2013)                                         |
| Morocco                  | 197 550 (OIE, 2014)          | 0.44 (OIE, 2014)                                         |
| Niger                    | 1 698 110 (OIE, 2013)        | 1.34 (OIE, 2013)                                         |
| Nigeria                  | 279 397                      | 0.3                                                      |
| Sudan                    | 4 830 000                    | 1.93                                                     |
| Somalia                  | 710 000                      | 11.13                                                    |
| Chad                     | 6 400 000                    | 4.98                                                     |
| Tunisia                  | 56 021                       | 0.34                                                     |
| **Middle East/Central Asia** |                          |                                                          |
| Afghanistan              | 175 270                      | 0.21                                                     |
| India<sup>a</sup>        | 400 000 (OIE, 2015)          | 0.12 (OIE, 2015)                                         |
| Iran<sup>b</sup>         | 171 500                      | 0.10                                                     |
| Iraq                     | 81 205                       | 0.19                                                     |
| Jordan                   | 10 872 (OIE, 2014)           | 0.12 (OIE, 2014)                                         |
| Kazakhstan<sup>b</sup>   | 170 513                      | 0.06                                                     |
| Kuwait                   | 80 790                       | 4.53                                                     |
| Oman                     | 257 713                      | 1.21                                                     |
| Pakistan<sup>b</sup>     | 1 000 000                    | 1.24                                                     |
| Qatar                    | 77 417 (OIE, 2014)           | 6.77 (OIE, 2014)                                         |
| Saudi Arabia             | 481 138                      | 0.25                                                     |
| Syria                    | 45 610                       | 0.25                                                     |
| Turkmenistan<sup>b</sup> | 122 900                      | 0.25                                                     |
| UAE                      | 392 667                      | 4.74                                                     |
| Uzbekistan<sup>b</sup>   | 14 800                       | 0.03                                                     |
| Yemen                    | 459 366                      | 0.87                                                     |

<sup>a</sup>Excluding China and Mongolia because the large majority of camel population are Bactrian camels.

<sup>b</sup>Camel population exists of both dromedary and Bactrian camels [66].
isolation, and did not find significant differences in MERS-CoV antibody levels [40].

**Animal origin**

Most studies that compared local camels with imported camels suggested that imported camels are seropositive for MERS-CoV more often [9, 17, 27, 34, 41], although not all differences were significant.

Two studies in Egypt found a significantly higher RNA positivity rate in imported camels from East Africa compared with domestically bred camels [17, 27], while another study executed in the KSA found a significantly higher number of MERS-CoV RNA-positive results amongst local camels vs. camels from Sudan and Somalia [22].

**Seasonal variation in MERS-CoV circulation in the camel population**

Although MERS-CoV was detected almost year-round in camels, some studies show a relatively higher seroprevalence and viral detection during the cooler winter months [17, 20, 27, 38].

**MERS-CoV in non-dromedary animals**

MERS-CoV antibodies have been detected in llamas and alpacas in Israel and in alpacas in Qatar [42, 43]. To date, no MERS-CoV antibodies or viral RNA have been detected in Bactrian camels [4, 37, 44–47] (Table 1 and Table 3). Swine, goats and horses that were included in the field surveys in our review all tested negative for MERS-CoV RNA and antibodies [4, 17, 31, 48–52]. MERS-CoV antibodies were detected in two studies in sheep in Egypt and Qatar, although in very low numbers [17, 51]. However, most surveys that investigated sheep did not find evidence of MERS-CoV infection or exposure [4, 23, 29, 31, 34, 48–51, 53].

**Discussion**

The publications in this review show that the MERS-CoV mainly circulates in dromedary camel populations in the Middle East and part of Africa, and has been infecting dromedary camels in Africa for more than three decades. Antibodies have also been found in Arabic camel sera from the early 90s [31, 32]. However, MERS-CoV was discovered until 2012, after the first human cases appeared [1], which is probably due to the minor clinical symptoms of MERS-CoV infections in camels [18]. Most camel surveys were conducted in the Middle East and some northern and eastern African countries, but significant data gaps currently still exist in the north and west of Africa, in countries that have camel populations of 100 000 to more than a million animals, such as Algeria, Libya, Mauritania and Niger. Even less is known about the central Asian region. Some evidence of MERS-CoV circulation in camels of Pakistan and Bangladesh was recently published, but data is lacking from Afghanistan and India. Knowledge on the presence of MERS-CoV in the animal reservoir is a crucial first step to assess whether MERS-CoV could be a relevant public health threat in these regions.

MERS-CoV infections are mainly detected in calves and young camels [30, 31]. The research included in this review shows that the IgG positivity rate increases gradually in dromedary camels of increasing age while the MERS-CoV RNA detection rate decreases. Maternal IgG antibodies in camels are acquired through the intake of colostrum during the first 24 h post-parturition. After 24 h, antibody levels in the dam’s milk decrease rapidly [54]. One study showed that maternal antibodies in calves peak at 7 days post-parturition and decline in the following 6 months. After 24 h, antibody levels in the dam’s milk decrease rapidly [54]. One study showed that maternal antibodies in calves peak at 7 days post-parturition and decline in the following 6 months. After 5–6 months, over half of the calves did not have maternal neutralizing antibodies in their serum any longer [30]. However, in other field studies, the titre of MERS-CoV-specific antibodies is still low at 1 month of age and increases with age in dromedary calves [27, 55]. A lower or undetectable antibody levels in young camels is likely to explain the higher MERS-CoV RNA detection rate. In

![Fig. 2. Virological and serological evidence for MERS CoV in dromedary camels.](https://doi.org/10.1017/S095026881800345X) Published online by Cambridge University Press
adult camels, a much higher MERS-CoV seroprevalence can be found, which is probably due to a long-lasting immune response against a MERS-CoV infection or multiple re-infections with MERS-CoV. Immunity is not sterilizing, as MERS-CoV infection and shedding have also been shown in adult camels that have MERS-CoV. Immunity is not sterilizing, as MERS-CoV infection and shedding have also been shown in adult camels that have MERS-CoV. Immunity is not sterilizing, as MERS-CoV infection and shedding have also been shown in adult camels that have MERS-CoV.

Immunity is not sterilizing, as MERS-CoV infection and shedding have also been shown in adult camels that have MERS-CoV. Immunity is not sterilizing, as MERS-CoV infection and shedding have also been shown in adult camels that have MERS-CoV.

Six additional sera from sheep in Qatar tested positive by protein microarray (pMA), but could not be confirmed by NT.

Articles that were not included in the original literature search, because no camels were investigated in these studies.

MERS-CoV RNA in nasal swabs.

Articles that were not included in the original literature search, because no camels were investigated in these studies.

MERS-CoV RNA in nasal swabs.

In experimental studies, llama’s and alpaca’s are shown to be susceptible to infection with MERS-CoV, which was confirmed by two papers in our review, describing serologically positive llamas and alpacas in Israel and alpacas with MERS-CoV neutralizing antibodies in Qatar. In experimental settings, animal-to-animal transmission has been shown for alpacas, making them a possible risk population for human infections. Two studies in our review also found anti-MERS-CoV antibodies in sheep and alpaca, respectively.

We show that dromedary camels are present in large parts of the African and Asian continent, and that MERS infections in dromedary camels are widespread. However, human infections due to spill-over from the dromedary camel reservoir have not been reported in Africa. Several explanations for the difference in human cases between the Arabian Peninsula and Africa have been suggested, such as differences in cultural habits, camel husbandry, prevalence of comorbidities, under detection or genetic factors in the local population. Moreover, West African viruses were found to be phylogenetically and

### Table 3. MERS-CoV in non-dromedary animals in the field

| Species          | Seroprevalence                                                                 | Viral RNA |
|------------------|-------------------------------------------------------------------------------|-----------|
| Bactrian camel   | 0% (0/505) (Netherlands, Chile [4]; UAE [37]; Mongolia [44]; China [45]; Kazakhstan [46]; Japan [47]) | 0/390 (China [45], Mongolia [44]) |
| Alpaca           | 24% (30/126) (Israel[+]) [43], Netherlands, Chile [4]) 100% (15/15), Qatar [42] | 0% (0/102) (Israel [43]) 0% (0/15) (Qatar: [42]) |
| Llama            | 23% (6/26) (Israel [+]) [43], Netherlands, Chile [4]) | 0% (0/19) (Israel [43]) |
| Guanaco          | 0% (0/2) (Chile [4]) | – |
| Cattle and buffalos | 0% (0/258) (KSA [50]; Egypt [27, 48]; The Netherlands [4]; Jordan [23, 51]) | 0% (0/35) (Egypt [27]) |
| Swine            | 0% (0/260) (Egypt [48]) | – |
| Sheep            | 0.2% (1/482) (KSA [31, 50]; Egypt (+) [27, 48], The Netherlands [4]; Jordan [23, 51]; UAE [29, 49]; Bangladesh [34]) | 0% (0/307) (Jordan [51]; KSA [31]; Egypt [27]; Bangladesh [34]) |
| Goats            | 0% (0/399) (KSA [31, 50]; Egypt [27, 48]; Spain, The Netherlands [4]; Jordan [51]) | 0% (0/72) (KSA [31]; Egypt [27]) |
| Horses, donkeys  | 0% (0/22) (Egypt [27]; UAE [49]) 0% (0/192) (UAE [52]) | 0% (0/19) (Egypt [27]) |
| Birds            | 0% (0/444) (KSA [50]; HK [48]) | – |
| Bats             | 0% (0/91) (Egypt [27]) | – |

*MERS-CoV RNA in nasal swabs.

Articles that were not included in the original literature search, because no camels were investigated in these studies.

Six additional sera from sheep in Qatar tested positive by protein microarray (pMA), but could not be confirmed by NT.
phenotypically distinct from the MERS-CoV viruses that caused human disease in the Middle East [65].

Increased knowledge on the animal reservoir of MERS-CoV needs to be combined with research on MERS prevalence and risk factors in humans to assess the true public health risk. Moreover, the absence of human disease, combined with the mild symptoms in camels, caused by MERS, will likely have a negative effect on the willingness to implement interventions and the cost-effectiveness of possible interventions in some areas.

Conclusion

Since the discovery of MERS-CoV in 2012, the dromedary camel has been identified as the animal reservoir of human infections with the MERS-CoV. However, the exact route of human primary infections is still unknown. Moreover, the scale of the spread and prevalence of MERS-CoV in the camel reservoir is not fully known yet since there is still a lack of MERS-CoV prevalence data in some countries that harbour a very significant proportion of the world camel population. However, knowledge of the animal reservoir of MERS-CoV is essential to develop intervention and control measures to prevent human infections. Prospective studies that include representative sampling of camels of different age groups and sex, within the different husbandry practices, are needed to fully understand the patterns of MERS-CoV circulation. Such studies are important as they may give more information on critical control points for interventions to reduce the circulation of MERS-CoV and/or exposure of humans.

Author ORCIDs. R. S. Sikkema, 0000-0001-7331-6274

Financial support. This study was financially supported by the European Commission’s H2020 programme under contract number 643476 (http://www.compare-europe.eu/).

Conflict of interest. None.

References

1. Zaki AM et al. (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. The New England Journal of Medicine 367, 1814–1820.
2. WHO-EMRO. MERS situation update March. Available at http://www.emro.who.int/images/stories/mers-cov/MERS-CoV_March_2018.pdf?ua=1 (Accessed 2 May 2018).
3. Haagmans BL et al. (2014) Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. The Lancet Infectious Diseases 14, 140–145.
4. Reusken CB et al. (2013) Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. The Lancet Infectious Diseases 13, 859–866.
5. Hui DS et al. (2018) Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. The Lancet Infectious Diseases 18, e217–e227.
6. WHO/MERS/RA. WHO MERS-CoV Global Summary and Assessment of Risk. Available at http://www.who.int/emergencies/mers-cov/risk-assessment-july-2017.pdf (Accessed 2 May 2018).
7. Dudas G et al. (2018) MERS-CoV spillover at the camel-human interface. Elife 7, e31257.
8. Anthony SJ et al. (2017) Further evidence for bats as the evolutionary source of Middle East respiratory syndrome coronavirus. mBio 8, e00373-17.
9. Chu DK et al. (2014) MERS coronaviruses in dromedary camels, Egypt. Emerging Infectious Diseases 20, 1049–1053.
10. FAO MERS-CoV situation updates. Available at http://www.fao.org/ag/againfo/programmes/en/empres/mers/situation_update.html (Accessed 2 May 2018).
11. FAO FAOSTAT. Available at http://www.fao.org/faostat/en/#data (Accessed 2 May 2018).
12. OIE World Animal Health Information System (WAHIS). Available at http://www.oie.int/wahis_2/public/wahid/home/ (Accessed 2 May 2018).
13. Faye B et al. (2013) La production de viande de chameau: état des connaissances, situation actuelle et perspectives. INRA Productions Animales 26, 247–258.
14. Saailield WK and Edwards GP (2010) Distribution and abundance of the feral camel (Camelus dromedarius) in Australia. The Rangeland Journal 32, 1–9.
15. Younan M, Bornstein S and Glueckv IV (2016) MERS and the dromedary camel trade between Africa and the Middle East. Tropical Animal Health and Production 48, 1277–1282.
16. FAO (2018) Somalia registers record exports of 5 million livestock in 2014. Available at http://www.fao.org/news/story/en/item/283777/icode/ (Accessed 19 June 2018).
17. Ali M et al. (2017) Cross-sectional surveillance of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels and other mammals in Egypt, August 2015 to January 2016. Eurosurveillance 22, 30487.
18. Adney DR et al. (2014) Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerging Infectious Diseases 20, 1999–2005.
19. Hemida MG et al. (2014) MERS coronavirus in dromedary camel herd, Saudi Arabia. Emerging Infectious Diseases 20, 1231–1234.
20. Khalafta AI et al. (2015) MERS-CoV in upper respiratory tract and lungs of dromedary camels, Saudi Arabia, 2013–2014. Emerging Infectious Diseases 21, 1153–1158.
21. Haagmans BL et al. (2016) An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 351, 77–81.
22. Sabir JS et al. (2016) Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science 351, 81–84.
23. van Doremalen N et al. (2017) High prevalence of Middle East respiratory coronavirus in young dromedary camels in Jordan. Vector-Borne and Zoonotic Diseases 17, 155–159.
24. Hemida MG et al. (2017) Longitudinal study of Middle East respiratory syndrome coronavirus infection in dromedary camel herds in Saudi Arabia, 2014–2015. Emerging Microbes & Infections 6, e56.
25. Woo PC et al. (2014) Novel betacoronavirus in dromedaries of the Middle East, 2013. Emerging Infectious Diseases 20, 560–572.
26. Farag EA et al. (2015) High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014. Infection Ecology & Epidemiology 5, 28305.
27. Ali MA et al. (2017) Systematic, active surveillance for Middle East respiratory syndrome coronavirus in camels in Egypt. Emerging Microbes & Infections 6, e1.
28. Reusken CB et al. (2014) Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014. Eurosurveillance 19, 20829.
29. Muhairi SA et al. (2016) Epidemiological investigation of Middle East respiratory syndrome coronavirus in dromedary camel farms linked with human infection in Abu Dhabi Emirate, United Arab Emirates. Virus Genes 52, 848–854.
30. Meyer B et al. (2016) Time course of MERS-CoV infection and immunity in dromedary camels. Emerging Infectious Diseases 22, 2171–2173.
31. Alagaili AN et al. (2014) Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio 5, e00884–14.
32. Muller MA et al. (2014) MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983–1997. Emerging Infectious Diseases 20, 2093–2095.
33. Gutierrez C et al. (2015) Presence of antibodies but no evidence for circulation of MERS-CoV in dromedaries on the Canary Islands, 2015. Eurosurveillance 20, 30019.
34. Islam A et al. (2018) Middle East respiratory syndrome coronavirus antibodies in dromedary camels, Bangladesh, 2015. Emerging Infectious Diseases 24, 926–928.
35. Saqib M et al. (2017) Serologic evidence for MERS-CoV infection in dromedary camels, Punjab, Pakistan, 2012–2015. Emerging Infectious Diseases 23, 550–551.
36. Corman VM et al. (2014) Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992–2013. Emerging Infectious Diseases 20, 1319–1322.
37. Meyer B et al. (2014) Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. Emerging Infectious Diseases 20, 552–559.
38. Kasem S et al. (2018) Cross-sectional study of MERS-CoV-specific RNA and antibodies in animals that had had contact with MERS patients in Saudi Arabia. Journal of Infection and Public Health 11, 331–338.
39. Miguel E et al. (2017) Risk factors for MERS coronavirus infection in dromedary camels in Burkina Faso, Ethiopia, and Morocco, 2015. Eurosurveillance 22, 30498.
40. Deem SL et al. (2015) Serological evidence of MERS-CoV antibodies in dromedary camels (Camelus dromedaries) in Laikipia County, Kenya. PLoS ONE 10, e0140125.
41. Yusof MF et al. (2017) Diversity of Middle East respiratory syndrome coronaviruses in 109 dromedary camels based on full-genome sequencing, Abu Dhabi, United Arab Emirates. Emerging Microbes & Infections 6, e0101.
42. Reusken CB et al. (2016) MERS-CoV infection of alpaca in a region where MERS-CoV is endemic. Emerging Infectious Diseases 22, 1129–1131.
43. David D et al. (2018) Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels. One Health 5, 65–68.
44. Chan SM et al. (2015) Absence of MERS-coronavirus in Bactrian camels, Southern Mongolia, November 2014. Emerging Infectious Diseases 21, 1269–1271.
45. Liu R et al. (2015) Absence of Middle East respiratory syndrome coronavirus in Bactrian camels in the West Inner Mongolia Autonomous Region of China: surveillance study results from July 2015. Emerging Microbes & Infections 4, e073.
46. Miguel E et al. (2016) Absence of Middle East respiratory syndrome coronavirus in camelds, Kazakhstan, 2015. Emerging Infectious Diseases 22, 555–557.
47. Shirato K et al. (2015) Middle East respiratory syndrome coronavirus infection not found in camels in Japan. Japanese Journal of Infectious Diseases 68, 256–258.
48. Perera RA et al. (2013) Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Eurosurveillance 18, 20574.
49. Alexandersen S et al. (2014) Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates, in 2005. Transboundary Emerging Diseases 61, 105–108.
50. Hemida MG et al. (2013) Middle East respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Eurosurveillance 18, 20659.
51. Reusken CB et al. (2013) Middle East respiratory syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Eurosurveillance 18, 20662.
52. Meyer B et al. (2015) Serologic assessment of possibility for MERS-CoV infection in equids. Emerging Infectious Diseases 21, 181–182.
53. Falzarano D et al. (2017) Dromedary camels in northern Mali have high seropositivity to MERS-CoV. One Health (Amsterdam, The Netherlands) 3, 41–43.
54. Kamber R et al. (2001) Studies on the supply of immunoglobulin G to newborn camel calves (Camelus dromedarius). Journal of Dairy Research 68, 1–7.
55. Wernery U et al. (2015) Acute Middle East respiratory syndrome coronavirus infection in livestock Dromedaries, Dubai, 2014. Emerging Infectious Diseases 21, 1019–1022.
56. Faye B (2014) The camel today: assets and potentials. Anthropozooologica 49, 167–176.
57. van Doremalen N, Bushmaker T and Munster VJ (2013) Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions. Eurosurveillance 18, 20590.
58. Cramer G et al. (2016) Experimental infection and response to rechallenge of alpacas with Middle East respiratory syndrome coronavirus. Emerging Infectious Diseases 22, 1071–1074.
59. Vergara-Alert J et al. (2017) Livestock susceptibility to infection with Middle East respiratory syndrome coronavirus. Emerging Infectious Diseases 23, 232–240.
60. Adney DR et al. (2016) Inoculation of goats, sheep, and horses with MERS-CoV does not result in productive viral shedding. Viruses 8, e230.
61. van Doremalen N et al. (2014) Host species restriction of Middle East respiratory coronavirus through its receptor, dipeptidyl peptidase 4. Journal of Virology 88, 9220–9232.
62. Vergara-Alert J et al. (2017) Middle East respiratory syndrome coronavirus experimental transmission using a pig model. Transboundary Emerging Diseases 64, 1342–1345.
63. de Wit E et al. (2017) Domestic pig unlikely reservoir for MERS-CoV. Emerging Infectious Diseases 23, 985–988.
64. Liljander A et al. (2016) MERS-CoV antibodies in humans, Africa, 2013–2014. Emerging Infectious Diseases 22, 1086–1089.
65. Chu D KW et al. (2018) MERS coronaviruses from camels in Africa exhibit region-dependent genetic diversity. Proceedings of the National Academy of Sciences 115, 3144–3149.
66. Ming L et al. (2017) Genetic diversity and phylogeographic structure of Bactrian camels shown by mitochondrial sequence variations. Animal Genetics 48, 217–220.
67. Azhar EI et al. (2014) Evidence for camel-to-human transmission of MERS coronavirus. The New England Journal of Medicine 370, 2499–2505.
68. Memish ZA et al. (2014) Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerging Infectious Diseases 20, 1012–1015.
69. Hemida MG et al. (2014) Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity. EuroSurveillance 19, 20828.
70. Nowotny N et al. (2014) Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels, Oman, 2013. Eurosurveillance 19, 20781.
71. Raj V et al. (2014) Isolation of MERS Coronavirus from a Dromedary Camel, Qatar, 2014. Emerging Infectious Diseases 20, 1339–1342.
72. Al Hammadi ZM et al. (2015) Asymptomatic MERS-CoV infection in humans possibly linked to infected dromedaries imported from Oman to United Arab Emirates, May 2015. Emerging Infectious Diseases 21, 2197–2200.
73. Chu D KW et al. (2015) Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Nigeria, 2015. Eurosurveillance 20, 30086.
74. Yusof MF et al. (2015) Prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Abu Dhabi Emirate, United Arab Emirates. Viruses Genes 50, 509–513.
75. Al-Salhi SF et al. (2017) Phylogenetic analysis of MERS-CoV in human and camels in Iraq. International Journal of Pharmaceutical Research & Allied Sciences 6, 53–58.
76. Munyaa P et al. (2017) No serologic evidence of Middle East respiratory syndrome coronavirus infection among camel farmers exposed to highly seropositive camel herds: a household linked study, Kenya, 2013. American Journal Tropical Medicine and Hygiene 96, 1318–1324.
77. Li Y et al. (2017) Identification of diverse viruses in upper respiratory samples in dromedary camels from United Arab Emirates. PLOS ONE 12, e0184718.
78. Harrath R et al. (2018) Sero-prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) specific antibodies in dromedary camels in Tabuk, Saudi Arabia. Journal of Medical Virology 90, 1285–1289.
79. Kasem S et al. (2018) The prevalence of Middle East respiratory Syndrome coronavirus (MERS-CoV) infection in livestock and temporal relation to locations and seasons. Journal of Infection and Public Health 11, 884–888.